Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : BioSenic
Deal Size : Undisclosed
Deal Type : Agreement
BioSenic Reaches Agreement with Phebra on Oral Arsenic Trioxide Development for cGvHD
Details : The agreement aims for the development of the first oral formulation of ArsciCor (arsenic troxide) in the field of several targeted autoimmune diseases, including for cGvHD treatment.
Product Name : ArsciCor
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
January 15, 2024
Lead Product(s) : Arsenic Trioxide
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : BioSenic
Deal Size : Undisclosed
Deal Type : Agreement